{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:57:41Z","timestamp":1793761061571,"version":"4.6.1"},"reference-count":184,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint molecules play a central role in regulating T cell function, maintaining immune homeostasis, and facilitating tumor immune evasion, making them critical targets in cancer immunotherapy. This review provides a comprehensive overview of the structural characteristics and signaling mechanisms of key co-inhibitory and co-stimulatory molecules, and their immunoregulatory roles in both solid tumors and hematological malignancies. Recent advances in the clinical application of immune checkpoint inhibitors, combination therapy strategies, and mechanisms of resistance are discussed. Furthermore, the importance of multi-target combinatorial approaches and personalized immune modulation is emphasized, offering valuable insights and directions for optimizing cancer immunotherapy strategies.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1674818","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:40:43Z","timestamp":1768372843000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["The role of immune checkpoint molecules in cancers"],"prefix":"10.3389","volume":"16","author":[{"given":"Meilan","family":"Zhang","sequence":"first","affiliation":[{"name":"The Affiliated Panyu Central Hospital of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Xu","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center (SYSUCC)","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaokuan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Huadu District People\u2019s Hospital of Guangzhou","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyun","family":"Guo","sequence":"additional","affiliation":[{"name":"The Affiliated Panyu Central Hospital of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[{"name":"The Affiliated Panyu Central Hospital of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingqing","family":"Zhou","sequence":"additional","affiliation":[{"name":"The Affiliated Panyu Central Hospital of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailin","family":"Tang","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center (SYSUCC)","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewei","family":"Zhu","sequence":"additional","affiliation":[{"name":"The First People's Hospital of Foshan (The Affiliated Foshan Hospital of Southern University of Science and Technology), School of Medicine, Southern University of Science and Technology","place":["Foshan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.5662\/wjm.v13.i3.79","article-title":"Immunotherapy for advanced gastric cancer","volume":"13","author":"Leowattana","year":"2023","journal-title":"World J Methodol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3747\/co.27.5223","article-title":"A review of cancer immunotherapy: from the past, to the present, to the future","volume":"27","author":"Esfahani","year":"2020","journal-title":"Curr Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12943-022-01655-0","article-title":"TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma","volume":"21","author":"Jiang","year":"2022","journal-title":"Mol Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"100089","DOI":"10.1016\/j.modpat.2022.100089","article-title":"Nonredundant upregulation of CD112R (PVRIG) and PD-1 on cytotoxic T lymphocytes located in T cell nests of colorectal cancer","volume":"36","author":"Yang","year":"2023","journal-title":"Mod Pathol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e152864","DOI":"10.1172\/JCI152864","article-title":"Tim-3 mediates T cell trogocytosis to limit antitumor immunity","volume":"132","author":"Pagliano","year":"2022","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.immuni.2022.03.013","article-title":"Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity","volume":"55","author":"Maruhashi","year":"2022","journal-title":"Immunity"},{"key":"B10","doi-asserted-by":"publisher","first-page":"121083","DOI":"10.1016\/j.lfs.2022.121083","article-title":"VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated","volume":"310","author":"Mortezaee","year":"2022","journal-title":"Life Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"106269","DOI":"10.1016\/j.phrs.2022.106269","article-title":"A novel immune checkpoint siglec-15 antibody inhibits LUAD by modulating mphi polarization in TME","volume":"181","author":"Xiao","year":"2022","journal-title":"Pharmacol Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1298571","article-title":"The role of immune checkpoints in antitumor response: a potential antitumor immunotherapy","volume":"14","author":"Mejia-Guarnizo","year":"2023","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"106002","DOI":"10.1016\/j.biocel.2021.106002","article-title":"The biology of combination immunotherapy in recurrent metastatic head and neck cancer","volume":"136","author":"Yuan","year":"2021","journal-title":"Int J Biochem Cell Biol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2020.02.006","article-title":"ADORA1 inhibition promotes tumor immune evasion by regulating the ATF3-PD-L1 axis","volume":"37","author":"Liu","year":"2020","journal-title":"Cancer Cell"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-22-0896","article-title":"ANXA1 promotes tumor immune evasion by binding PARP1 and upregulating stat3-induced expression of PD-L1 in multiple cancers","volume":"11","author":"Xiao","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1189953","article-title":"Glycolytic enzyme HK2 promotes PD-L1 expression and breast cancer cell immune evasion","volume":"14","author":"Lin","year":"2023","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"115514","DOI":"10.1016\/j.biopha.2023.115514","article-title":"Cancer cell-intrinsic PD-1: Its role in Malignant progression and immunotherapy","volume":"167","author":"Chen","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-022-01325-0","article-title":"Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts","volume":"15","author":"Wang","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01091-9","article-title":"Vax-Innate: improving therapeutic cancer vaccines by modulating T cells and the tumour microenvironment","volume":"25","author":"Baharom","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-023-03520-x","article-title":"Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma variant","volume":"482","author":"El","year":"2023","journal-title":"Virchows Arch"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1288172","article-title":"Checkpoint inhibition in hematologic Malignancies","volume":"13","author":"Tsumura","year":"2023","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"6661406","DOI":"10.1155\/2021\/6661406","article-title":"Current and future perspectives of PD-1\/PDL-1 blockade in cancer immunotherapy","volume":"2021","author":"Makuku","year":"2021","journal-title":"J Immunol Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02895-x","article-title":"Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis","volume":"30","author":"Thomas","year":"2024","journal-title":"Nat Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02010","article-title":"Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as complementary biomarker for immune checkpoint inhibition in non-small-cell lung cancer","volume":"40","author":"Park","year":"2022","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy","volume":"16","author":"Cai","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e70412","DOI":"10.1002\/mco2.70412","article-title":"The role of immune checkpoint inhibitors in cancer therapy: mechanism and therapeutic advances","author":"Chen","year":"2025","journal-title":"MedComm(2020)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.07.040189.002305","article-title":"Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy","volume":"7","author":"Mueller","year":"1989","journal-title":"Annu Rev Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.13.5031","article-title":"T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7\/BB-1","volume":"87","author":"Linsley","year":"1990","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.04.020","article-title":"CD28 costimulation: from mechanism to therapy","volume":"44","author":"Esensten","year":"2016","journal-title":"Immunity"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1198365","article-title":"Current understanding of CTLA-4: from mechanism to autoimmune diseases","volume":"14","author":"Hossen","year":"2023","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/35105024","article-title":"T-cell regulation by CD28 and CTLA-4","volume":"1","author":"Alegre","year":"2001","journal-title":"Nat Rev Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(94)90071-X","article-title":"CTLA-4 can function as a negative regulator of T cell activation","volume":"1","author":"Walunas","year":"1994","journal-title":"Immunity"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/328267a0","article-title":"A new member of the immunoglobulin superfamily--CTLA-4","volume":"328","author":"Brunet","year":"1987","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1158\/2326-6066.CIR-20-0253","article-title":"CD28 costimulatory domain-targeted mutations enhance chimeric antigen receptor T-cell function","volume":"9","author":"Boucher","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"eaay8248","DOI":"10.1126\/scisignal.aay8248","article-title":"4-1BB costimulation promotes CAR T cell survival through noncanonical NF-kappaB signaling","volume":"13","author":"Philipson","year":"2020","journal-title":"Sci Signal"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adg0878","article-title":"Sustained CD28 costimulation is required for self-renewal and differentiation of TCF-1(+) PD-1(+) CD8 T cells","volume":"8","author":"Humblin","year":"2023","journal-title":"Sci Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01061-1","article-title":"CD28 co-stimulation: novel insights and applications in cancer immunotherapy","volume":"24","author":"Lotze","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/16717","article-title":"ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28","volume":"397","author":"Hutloff","year":"1999","journal-title":"Nature"},{"key":"B41","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.molimm.2014.01.008","article-title":"Inducible costimulator facilitates T-dependent B cell activation by augmenting IL-4 translation","volume":"59","author":"Gigoux","year":"2014","journal-title":"Mol Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e000544","DOI":"10.1136\/esmoopen-2019-000544","article-title":"The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy","volume":"5","author":"Solinas","year":"2020","journal-title":"ESMO Open"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S401123","article-title":"ICOS\/ICOSLG and PD-1 co-expression is associated with the progression of colorectal precancerous- carcinoma immune microenvironment","volume":"16","author":"Zhang","year":"2023","journal-title":"J Inflammation Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e1141857","DOI":"10.1080\/2162402X.2016.1141857","article-title":"The clinical impact of ICOS signal in colorectal cancer patients","volume":"5","author":"Zhang","year":"2016","journal-title":"Oncoimmunology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.6.1963","article-title":"cDNA sequences of two inducible T-cell genes","volume":"86","author":"Kwon","year":"1989","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.968360","article-title":"4-1BB: A promising target for cancer immunotherapy","volume":"12","author":"Kim","year":"2022","journal-title":"Front Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02618","article-title":"CD137 (4-1BB) signalosome: complexity is a matter of TRAFs","volume":"9","author":"Zapata","year":"2018","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1256360","article-title":"Recent research and clinical progress of CTLA-4-based immunotherapy for breast cancer","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"B50","doi-asserted-by":"publisher","first-page":"112389","DOI":"10.1016\/j.bios.2020.112389","article-title":"Force-dependent trans-endocytosis by breast cancer cells depletes costimulatory receptor CD80 and attenuates T cell activation","volume":"165","author":"Park","year":"2020","journal-title":"Biosens Bioelectron"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.013","article-title":"The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection","volume":"41","author":"Staron","year":"2014","journal-title":"Immunity"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.60114","article-title":"New insights into the important roles of tumor cell-intrinsic PD-1","volume":"17","author":"Zheng","year":"2021","journal-title":"Int J Biol Sci"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00867-9","article-title":"Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1","volume":"23","author":"Chamoto","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-020-03737-y","article-title":"Transcriptional and epigenetic regulation of PD-1 expression","volume":"78","author":"Chi","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2011.06.015","article-title":"Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells","volume":"35","author":"Youngblood","year":"2011","journal-title":"Immunity"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1206370109","article-title":"Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1","volume":"109","author":"Xiao","year":"2012","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1080\/08830185.2017.1326784","article-title":"In this issue: Role of immune cells, immune modulating factors and immunotoxins in cancer immunotherapy","volume":"36","author":"Kumar","year":"2017","journal-title":"Int Rev Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","article-title":"Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway","volume":"21","author":"Ohaegbulam","year":"2015","journal-title":"Trends Mol Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00550","article-title":"The PD1:PD-L1\/2 pathway from discovery to clinical implementation","volume":"7","author":"Bardhan","year":"2016","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01140-2","article-title":"Catch and release: freeing up PD-L1 ameliorates autoimmunity","volume":"23","author":"Grebinoski","year":"2022","journal-title":"Nat Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0620-x","article-title":"PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer","volume":"21","author":"Diskin","year":"2020","journal-title":"Nat Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1186\/s12885-024-12390-8","article-title":"PD-L1 knockdown suppresses vasculogenic mimicry of non-small cell lung cancer by modulating ZEB1-triggered EMT","volume":"24","author":"Li","year":"2024","journal-title":"BMC Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.11.5744","article-title":"Characterization of the major histocompatibility complex class II binding site on LAG-3 protein","volume":"94","author":"Huard","year":"1997","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830250949","article-title":"CD4\/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins","volume":"25","author":"Huard","year":"1995","journal-title":"Eur J Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202301018R","article-title":"Advancement of anti-LAG-3 in cancer therapy","volume":"37","author":"Li","year":"2023","journal-title":"FASEB J"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.785091","article-title":"Immune checkpoint LAG3 and its ligand FGL1 in cancer","volume":"12","author":"Shi","year":"2021","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12943-025-02355-1","article-title":"Clinical approaches to overcome PARP inhibitor resistance","volume":"24","author":"Zou","year":"2025","journal-title":"Mol Cancer"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1943180","DOI":"10.1080\/2162402X.2021.1943180","article-title":"PD-L1\/LAG-3 bispecific antibody enhances tumor-specific immunity","volume":"10","author":"Jiang","year":"2021","journal-title":"Oncoimmunology"},{"key":"B71","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3390\/jpm11070651","article-title":"The role of soluble LAG3 and soluble immune checkpoints profile in advanced head and neck cancer: A pilot study","volume":"11","author":"Botticelli","year":"2021","journal-title":"J Pers Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1758835920937612","DOI":"10.1177\/1758835920937612","article-title":"Efficacy of PD-1\/PD-L1 blockade monotherapy in clinical trials","volume":"12","author":"Zhao","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/ni739","article-title":"Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family","volume":"2","author":"McIntire","year":"2001","journal-title":"Nat Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1126\/science.1148536","article-title":"Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells","volume":"318","author":"Anderson","year":"2007","journal-title":"Science"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400557","article-title":"Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion","volume":"193","author":"Ferris","year":"2014","journal-title":"J Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2871","article-title":"Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion","volume":"18","author":"Rangachari","year":"2012","journal-title":"Nat Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/ni988","article-title":"Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance","volume":"4","author":"Sabatos","year":"2003","journal-title":"Nat Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2005.06.008","article-title":"The TIM gene family regulates autoimmune and allergic diseases","volume":"11","author":"Meyers","year":"2005","journal-title":"Trends Mol Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.3.1411","article-title":"Soluble form of T cell Ig mucin 3 is an inhibitory molecule in T cell-mediated immune response","volume":"176","author":"Geng","year":"2006","journal-title":"J Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2376","article-title":"Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1","volume":"13","author":"Chiba","year":"2012","journal-title":"Nat Immunol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13045-018-0667-4","article-title":"Tim-3 expression and its role in hepatocellular carcinoma","volume":"11","author":"Liu","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3390\/ph14030200","article-title":"TIGIT\/CD226 axis regulates anti-tumor immunity","volume":"14","author":"Yeo","year":"2021","journal-title":"Pharm (Basel)"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1172\/JCI81187","article-title":"TIGIT predominantly regulates the immune response via regulatory T cells","volume":"125","author":"Kurtulus","year":"2015","journal-title":"J Clin Invest"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1250258","article-title":"Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells in vitro","volume":"14","author":"Brauneck","year":"2023","journal-title":"Front Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"e004794","DOI":"10.1136\/jitc-2022-004794","article-title":"TIGIT blockade repolarizes AML-associated TIGIT(+) M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis","volume":"10","author":"Brauneck","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1548772","article-title":"Advances in CAR optimization strategies based on CD28","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40164-025-00618-7","article-title":"CD28 is superior to 4-1BB costimulation in generating CAR-NK cells for tumor immunotherapy","volume":"14","author":"Zhang","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1002\/jso.27725","article-title":"Expression of CD28, FAS, PD1, and CTLA4 molecules in the blood of women with triple-negative breast cancer","volume":"130","author":"Salgado","year":"2024","journal-title":"J Surg Oncol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s13046-023-02846-3","article-title":"CD28\/PD1 co-expression: dual impact on CD8(+) T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients\u2019 survival and ICB response","volume":"42","author":"Palermo","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"B91","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1080\/1354750X.2024.2435867","article-title":"Peripheral blood CD8 + CD28+ T cells as predictive biomarkers for treatment response in metastatic colorectal cancer","volume":"30","author":"Fei","year":"2025","journal-title":"Biomarkers"},{"key":"B92","doi-asserted-by":"publisher","first-page":"e011323","DOI":"10.1136\/jitc-2024-011323","article-title":"Potency-optimized CD28-activating bispecific antibody for the targeted treatment of Nectin-4 positive cancers","volume":"13","author":"Kaur","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B93","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41698-025-00933-6","article-title":"Unlocking the potential of TIGIT in enhancing therapeutic strategies for acute myeloid leukemia through combined azacitidine therapy","volume":"9","author":"Zhang","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-4256","article-title":"First-in-human phase I\/II ICONIC trial of the ICOS agonist vopratelimab alone and with nivolumab: ICOS-high CD4 T-cell populations and predictors of response","volume":"28","author":"Yap","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1963","article-title":"Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced\/metastatic solid tumors or lymphomas","volume":"28","author":"Meric-Bernstam","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-022-01781-7","article-title":"Immuno-PET monitoring of CD8(+) T cell infiltration post ICOS agonist antibody treatment alone and in combination with PD-1 blocking antibody using a (89)Zr anti-CD8(+) mouse minibody in EMT6 syngeneic tumor mouse","volume":"25","author":"Alsaid","year":"2023","journal-title":"Mol Imaging Biol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130590","article-title":"Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy","volume":"211","author":"Fan","year":"2014","journal-title":"J Exp Med"},{"key":"B98","doi-asserted-by":"publisher","first-page":"e011564","DOI":"10.1136\/jitc-2025-011564","article-title":"ICOS-expressing CAR-T cells mediate durable eradication of triple-negative breast cancer and metastasis","volume":"13","author":"Herbrich","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-23-1092","article-title":"Complement factor H is an ICOS ligand modulating tregs in the glioma microenvironment","volume":"13","author":"Smolag","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B100","doi-asserted-by":"publisher","first-page":"e010728","DOI":"10.1136\/jitc-2024-010728","article-title":"Fc-competent TIGITx4-1BB bispecific antibody exerts potent long-lasting antitumor activity by potentiating CD8(+) T cell activity and Fcgamma receptor-mediated modulation of the tumor microenvironment","volume":"13","author":"Son","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B101","doi-asserted-by":"publisher","first-page":"e006704","DOI":"10.1136\/jitc-2023-006704","article-title":"CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation","volume":"11","author":"Gao","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B102","doi-asserted-by":"publisher","first-page":"e005471","DOI":"10.1136\/jitc-2022-005471","article-title":"First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors","volume":"10","author":"Hamid","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000320","article-title":"Targeting neuropilin-1 abolishes anti-PD-1-upregulated regulatory T cells and synergizes with 4-1BB agonist for liver cancer treatment","volume":"78","author":"Wu","year":"2023","journal-title":"Hepatology"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1363568","article-title":"Circulating tumor-associated antigen-specific IFNgamma(+)4-1BB(+) CD8(+) T cells as peripheral biomarkers of treatment outcomes in patients with pancreatic cancer","volume":"15","author":"Murakami","year":"2024","journal-title":"Front Immunol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"7114","DOI":"10.3390\/ijms24087114","article-title":"Circulating CD137(+) T cell levels are correlated with response to pembrolizumab treatment in advanced head and neck cancer patients","volume":"24","author":"Cirillo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B106","doi-asserted-by":"publisher","first-page":"116800","DOI":"10.1016\/j.biopha.2024.116800","article-title":"PD-1-CD28-enhanced receptor and CD19 CAR-modified tumor-infiltrating T lymphocytes produce potential anti-tumor ability in solid tumors","volume":"175","author":"Chen","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-24-0037","article-title":"Peripheral blood-derived PD-1\/CD28-CD19 CAR-modified PD-1+ T-cell therapy in patients with solid tumors","volume":"12","author":"Zhang","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2955","article-title":"Targeting the inducible T-cell costimulator (ICOS) in patients with relapsed\/refractory T-follicular helper phenotype peripheral T-cell and angioimmunoblastic T-cell lymphoma","volume":"29","author":"Chavez","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2973","article-title":"First-in-human study of utomilumab, a 4-1BB\/CD137 agonist, in combination with rituximab in patients with follicular and other CD20(+) non-hodgkin lymphomas","volume":"26","author":"Gopal","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00975","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study","volume":"41","author":"Johnson","year":"2023","journal-title":"J Clin Oncol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s00262-024-03794-3","article-title":"Preclinical development of a novel CCR8\/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs","volume":"73","author":"Guo","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B113","doi-asserted-by":"publisher","first-page":"e007785","DOI":"10.1136\/jitc-2023-007785","article-title":"XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer","volume":"11","author":"Jenkins","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae135","article-title":"Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas","volume":"26","author":"Kim","year":"2024","journal-title":"Neuro Oncol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41419-023-06391-x","article-title":"Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy","volume":"15","author":"Babamohamadi","year":"2024","journal-title":"Cell Death Dis"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.52","article-title":"Nivolumab: targeting PD-1 to bolster antitumor immunity","volume":"11","author":"Brahmer","year":"2015","journal-title":"Future Oncol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1012-5","article-title":"Cemiplimab: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"B120","doi-asserted-by":"publisher","first-page":"e001246","DOI":"10.1136\/jitc-2020-001246","article-title":"Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis","volume":"8","author":"Apolo","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1635115","article-title":"Durvalumab in cancer medicine: a comprehensive review","volume":"19","author":"Alvarez-Argote","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"B122","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ctrv.2017.10.002","article-title":"PD-1 blockade in advanced NSCLC: A focus on pembrolizumab","volume":"62","author":"Peters","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"Placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30156-X","article-title":"Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study","volume":"21","author":"Lee","year":"2020","journal-title":"Lancet Oncol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S1470-2045(21)00151-0","article-title":"Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial","volume":"22","author":"Galle","year":"2021","journal-title":"Lancet Oncol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25397","article-title":"PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients","volume":"128","author":"Shi","year":"2011","journal-title":"Int J Cancer"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1158\/1078-0432.CCR-20-2400","article-title":"Modification of extracellular matrix enhances oncolytic adenovirus immunotherapy in glioblastoma","volume":"27","author":"Kiyokawa","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B132","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41388-018-0451-5","article-title":"Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade","volume":"38","author":"Qin","year":"2019","journal-title":"Oncogene"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30081-0","article-title":"Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial","volume":"19","author":"Atkins","year":"2018","journal-title":"Lancet Oncol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30324-7","article-title":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study","volume":"21","author":"Domchek","year":"2020","journal-title":"Lancet Oncol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12708","article-title":"Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy","volume":"283","author":"Chowdhury","year":"2018","journal-title":"J Intern Med"},{"key":"B136","doi-asserted-by":"publisher","first-page":"e003000","DOI":"10.1136\/jitc-2021-003000","article-title":"Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids","volume":"9","author":"Hamdan","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz123","article-title":"Hyperprogressive disease during PD-1\/PD-L1 blockade in patients with non-small-cell lung cancer","volume":"30","author":"Kim","year":"2019","journal-title":"Ann Oncol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-020-00651-5","article-title":"KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6\/MerTK signaling pathway","volume":"28","author":"Du","year":"2021","journal-title":"Cell Death Differ"},{"key":"B139","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ccell.2022.01.001","article-title":"Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments","volume":"40","author":"Kumagai","year":"2022","journal-title":"Cancer Cell"},{"key":"B140","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s12032-014-0082-9","article-title":"The effect of immune microenvironment on the progression and prognosis of colorectal cancer","volume":"31","author":"Chen","year":"2014","journal-title":"Med Oncol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"e1239005","DOI":"10.1080\/2162402X.2016.1239005","article-title":"LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma","volume":"5","author":"Deng","year":"2016","journal-title":"Oncoimmunology"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1003345107","article-title":"Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer","volume":"107","author":"Matsuzaki","year":"2010","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B143","doi-asserted-by":"publisher","first-page":"1736792","DOI":"10.1080\/2162402X.2020.1736792","article-title":"LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma\/T cell co-cultures","volume":"9","author":"Gestermann","year":"2020","journal-title":"Oncoimmunology"},{"key":"B144","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/j.celrep.2020.01.076","article-title":"Small molecule inhibition of GSK-3 specifically inhibits the transcription of inhibitory co-receptor LAG-3 for enhanced anti-tumor immunity","volume":"30","author":"Rudd","year":"2020","journal-title":"Cell Rep"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-0836","article-title":"TSR-033, a novel therapeutic antibody targeting LAG-3, enhances T-cell function and the activity of PD-1 blockade in vitro and in vivo","volume":"18","author":"Ghosh","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02172","article-title":"Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma","volume":"42","author":"Hamid","year":"2024","journal-title":"J Clin Oncol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"e432054","DOI":"10.1200\/EDBK_432054","article-title":"Advancements in urothelial cancer care: optimizing treatment for your patient","volume":"44","author":"Hemenway","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05368-8","article-title":"Neoadjuvant relatlimab and nivolumab in resectable melanoma","volume":"611","author":"Amaria","year":"2022","journal-title":"Nature"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01636","article-title":"First-line nivolumab and relatlimab plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma: the phase II RELATIVITY-060 study","volume":"42","author":"Hegewisch-Becker","year":"2024","journal-title":"J Clin Oncol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andre","year":"2020","journal-title":"N Engl J Med"},{"key":"B151","doi-asserted-by":"publisher","first-page":"e008689","DOI":"10.1136\/jitc-2023-008689","article-title":"Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study","volume":"12","author":"Overman","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1535","article-title":"Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas","volume":"23","author":"Kim","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B153","doi-asserted-by":"publisher","first-page":"e007854","DOI":"10.1136\/jitc-2023-007854","article-title":"Epithelium\/imcDC2 axis facilitates the resistance of neoadjuvant anti-PD-1 in human NSCLC","volume":"12","author":"Chen","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v15.i12.2138","article-title":"Combined TIM-3 and PD-1 blockade restrains hepatocellular carcinoma development by facilitating CD4+ and CD8+ T cell-mediated antitumor immune responses","volume":"15","author":"Zhang","year":"2023","journal-title":"World J Gastrointest Oncol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg6752","article-title":"Identification of a small-molecule Tim-3 inhibitor to potentiate T cell-mediated antitumor immunotherapy in preclinical mouse models","volume":"15","author":"Ma","year":"2023","journal-title":"Sci Transl Med"},{"key":"B156","doi-asserted-by":"publisher","first-page":"115583","DOI":"10.1016\/j.bcp.2023.115583","article-title":"Identification of a novel small-molecule inhibitor targeting TIM-3 for cancer immunotherapy","volume":"212","author":"Wu","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0140-4","article-title":"Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-kappaB\/IL-6\/STAT3 axis","volume":"37","author":"Zhang","year":"2018","journal-title":"Oncogene"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.04.003","article-title":"Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception","volume":"43","author":"Zhu","year":"2025","journal-title":"Cancer Cell"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4405","article-title":"Blocking TIM-3 in treatment-refractory advanced solid tumors: A phase ia\/b study of LY3321367 with or without an anti-PD-L1 antibody","volume":"27","author":"Harding","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B160","doi-asserted-by":"publisher","first-page":"e175257","DOI":"10.1172\/jci.insight.175257","article-title":"Combination of locoregional radiotherapy with a TIM-3 aptamer improves survival in diffuse midline glioma models","volume":"9","author":"Ausejo-Mauleon","year":"2024","journal-title":"JCI Insight"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2025.11.009","article-title":"PRDM15 inhibits responses of Tissue-Resident memory T cells by activating PVR\/TIGIT axis to mediate gastric cancer immunosuppression","author":"Zhang","year":"2025","journal-title":"J Adv Res"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1649078","article-title":"CD155-TIGIT\/CD96\/CD226 immune checkpoint axis interacting with tumor-infiltrating lymphocytes to exhibit diverse prognostic effects on breast cancer: a cohort study","volume":"16","author":"Ou","year":"2025","journal-title":"Front Immunol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"115722","DOI":"10.1016\/j.intimp.2025.115722","article-title":"Corrigendum to \u201cEnhancing anti-tumor immunity through TIGIT blockade and tumor-directed targeting in pancreatic cancer\u201d [Int","author":"Um","year":"2025","journal-title":"Immunopharmacol. 167 (2025) 115653]. Int Immunopharmacol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1568664","article-title":"pioneering the next era of cancer immunotherapy","volume":"16","author":"Ghasemi","year":"2025","journal-title":"Front Pharmacol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1626367","article-title":"Identification of a TIGIT-expressing CD8(+) T cell subset as a potential prognostic biomarker in colorectal cancer","volume":"16","author":"Cao","year":"2025","journal-title":"Front Immunol"},{"key":"B166","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s43018-025-00908-3","article-title":"Publisher Correction: TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation","volume":"6","author":"Nutsch","year":"2025","journal-title":"Nat Cancer"},{"key":"B167","doi-asserted-by":"publisher","first-page":"2419838","DOI":"10.1080\/19420862.2024.2419838","article-title":"Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies","volume":"16","author":"Zhang","year":"2024","journal-title":"MAbs"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-686550","article-title":"Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas","volume":"127","author":"Georgiou","year":"2016","journal-title":"Blood"},{"key":"B171","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12943-019-0977-3","article-title":"MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1\/PD-L1-mediated lymphoma cell interaction with CD8+T cells","volume":"18","author":"Zheng","year":"2019","journal-title":"Mol Cancer"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1126\/science.aac9935","article-title":"MYC regulates the antitumor immune response through CD47 and PD-L1","volume":"352","author":"Casey","year":"2016","journal-title":"Science"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.148965","article-title":"Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia","volume":"102","author":"Shapiro","year":"2017","journal-title":"Haematologica"},{"key":"B174","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.3390\/cancers13092112","article-title":"LAG-3 blockade with relatlimab (BMS-986016) restores anti-leukemic responses in chronic lymphocytic leukemia","volume":"13","author":"Sordo-Bahamonde","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26771","article-title":"The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma","volume":"10","author":"Chen","year":"2019","journal-title":"Oncotarget"},{"key":"B176","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-020-00853-x","article-title":"Expression patterns of immune checkpoints in acute myeloid leukemia","volume":"13","author":"Chen","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-792267","article-title":"Dual PD1\/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia","volume":"131","author":"Wierz","year":"2018","journal-title":"Blood"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02593-0","article-title":"The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial","volume":"29","author":"Luke","year":"2023","journal-title":"Nat Med"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12962","article-title":"Sabatolimab (MBG453) model-informed drug development for dose selection in patients with myelodysplastic syndrome\/acute myeloid leukemia and solid tumors","volume":"12","author":"Xu","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27161","article-title":"Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes","volume":"99","author":"Brunner","year":"2024","journal-title":"Am J Hematol"},{"key":"B181","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s00262-025-04024-0","article-title":"The effect of TIGIT and PD1 expression on T cell function and prognosis in adult patients with acute myeloid leukemia at diagnosis","volume":"74","author":"Xie","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B182","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.clim.2017.08.021","article-title":"CD8(+)T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients","volume":"190","author":"Wang","year":"2018","journal-title":"Clin Immunol"},{"key":"B183","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.3390\/biomedicines12102207","article-title":"The functional and prognostic impact of TIGIT expression on bone marrow NK cells in core binding factor-acute myeloid leukemia patients at diagnosis","volume":"12","author":"Xie","year":"2024","journal-title":"Biomedicines"},{"key":"B184","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/HEP.0000000000000934","article-title":"Platelet-mediated circulating tumor cell evasion from natural killer cell killing through immune checkpoint CD155-TIGIT","volume":"81","author":"Sun","year":"2025","journal-title":"Hepatology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1674818\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:39:27Z","timestamp":1771911567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1674818\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":184,"alternative-id":["10.3389\/fimmu.2025.1674818"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1674818","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"article-number":"1674818"}}